7 patents
Utility
Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases
3 Jan 23
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC.
Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø
Filed: 12 May 15
Utility
Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies
20 Sep 22
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma.
Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø
Filed: 26 Oct 16
Utility
Use of Substituted Hexitols Including Dianhydrogalactitol and Analogs to Treat Neoplastic Disease and Cancer Stem Cells Including Glioblastoma Multiforme and Medulloblastoma
23 Jun 22
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma.
Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
Filed: 8 Mar 22
Utility
Use of Substituted Hexitols Including Dianhydrogalactitol and Analogs to Treat Neoplastic Disease and Cancer Stem Cells Including Glioblastoma Multiforme and Medulloblastoma
12 May 22
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma.
Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
Filed: 24 Jan 22
Utility
Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma
1 Feb 22
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma.
Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
Filed: 8 Jan 19
Utility
Methods for Treating a Cancer Resistant to at Least One Tyrosine Kinase Inhibitor
19 Aug 21
Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI-1 gene are disclosed.
Dennis M. Brown, Jeffrey A. Bacha, William J. Garner
Filed: 17 Feb 21
Utility
Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
8 Jun 21
Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed.
Dennis M. Brown, Kent C. Shih, Anne Steino, Richard Schwartz, Sarath Kanekal, Howard A. Burris, III, Jeffrey A. Bacha, William J. Garner, Shaun Fouse
Filed: 9 Apr 15
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first